In Europe, the orthopedic biomaterial market continues to be hampered by the
economic difficulties experienced throughout the region; however, favorable
demographic trends and the adoption of new products will counteract these
market limiters, ultimately supporting modest revenue growth.
RESEARCH METHODOLOGY
This report uses a number of methodologies to gather and present data and
analysis. At the outset, a large survey of secondary sources is conducted.
These sources act as the basis for the primary research stage, which builds
and enhances the quantitative and qualitative attributes of the early research.
Secondary sources include
government publications, such as documentation from securities
commissions, health care and statistical agencies, and regulatory and patent
authorities;
material provided by medical technology companies, including annual
reports, product brochures, and corporate profiles;
internal databases and reports, including previous reports on similar or
related topics; and
general Internet searches, medical literature, and newspaper and magazine
searches to identify various centers of specialization and articles that might
provide leads for primary research.
The secondary research stage builds the foundation for the primary research.
The primary research methodology has four steps:
Step 1: The first step involves an impartial scan of all the
information gathered during the secondary research stage to determine its
utility based on the specific requirements of this report. Each piece of
information is either discarded or marked as high- or low-priority and then
organized appropriately as determined by the structure and sectioning of the
report.
Step 2: At this stage, early assumptions are formed as to the
implications of the information for the various market segments. These
assumptions are then used to determine hypotheses using both inductive and
deductive approaches. On the quantitative front, these hypotheses result in
full historical and projected market data sets (market sizes - unit sales,
ASPs, and revenues - as well as market shares).
Step 3: At this stage, the research is in position for its most
important primary phase - expert interviews. Throughout the secondary research
phase, industry and medical experts are identified. These experts are then
contacted by telephone and asked to participate in interviews on recent trends
and developments in the industry. Interviews are either conducted at the time
of the initial call or scheduled at the convenience of the expert. Interview
questions are tailored to the expertise of each particular interviewee,
although in most cases, the most important questions are asked of all experts.
The questions are largely based on the assumptions and hypotheses developed in
Step 2, which are then augmented, discarded, or adjusted based on the views
and positions put forth. Attempts are made, whenever possible, to cross-check
the views of various experts against each other and to reach positions of
consensus on issues and market numbers.
In some cases, a sample of relevant physicians is surveyed or interviewed.
Physicians are asked to comment on various issues and trends, both in their
own practice and in the overall market. The responses provided are then used
to strengthen or augment the assumptions and hypotheses developed during the
primary research phase.
Step 4: The final stage of primary research involves individual and
group analysis by Millennium Research Group. All research results are assessed
and cross-checked thoroughly to determine their validity, relevance, and
weight. From this process, qualitative conclusions are reached and data points
finalized.
MARKETRACK METHODOLOGY
Millennium Research Group's Marketrack methodology involves recruiting
hospital personnel responsible for the management of medical equipment and
procedures to participate by providing procedure volumes, device usage data,
and brand-level pricing information on an ongoing basis. Hospital respondents
include facility managers, nurses, administrators, and physicians. Information
is generally collected on a quarterly basis and includes, but is not limited
to, numbers and types of procedures performed and devices used.
FORECAST METHODOLOGY
In addition to the research methodology outlined above, the following
"bottom-up" methodology is used to develop forecast assumptions for the report.
A comprehensive breakdown of various procedures and device unit sales is
prepared using data from several sources, including professional associations,
government statistics, and private research/media sources. Industry experts
and practitioners are consulted to ensure accuracy and verify observed trends.
As a cross-check, total industry revenues available through annual reports and
other sources are compared against modeled industry revenues.
Using the best estimates of industry experts, practitioners, private
research/media sources, and inhouse experts, year-by-year growth rates and
ASPs are applied individually to each subcategory to derive forecasts. These
estimates are cross-checked by industry experts (marketing managers, product
managers, company executives, etc.) and further refined.
Overall findings are compared against market and procedure forecasts published
by other sources to ensure reasonable estimates.
Companies Mentioned:
Alphatec Spine
Anika Therapeutics
AorTech International
ApaTech
Arthrex
Athersys
Baxter
B. Braun
Berkeley Advanced Biomaterials
Biocomposites
Biomatlante
Biomet
BioMimetic Therapeutics
Bioniche Pharma
Bioteck
BoneSupport
Ceramisys
Cerapedics
CERAVER
Croma-Pharma
curasan
DePuy
DJO Global
Documedica
Exactech
Ferring Pharmaceuticals
FH ORTHOPEDICS
Fidia Farmaceutici
Finceramica
Galderma
Geistlich
Genzyme
Goodman
Inoteb
Integra LifeSciences
ISTO Technologies
Johnson & Johnson
Kasios
Kyungwon Medical
Laboratoires Genevrier
Laboratoires Pierre Fabre
LCA Pharmaceutical
Lifecore Biomedical
Mathys AG Bettlach
MBA Grupo
Medtronic
Millenium Biologix
Mylan
NovaBone
NuVasive
Olympus
Orthovita
OSSACUR
Osteotech
Q-Med
Recordati
Rottapharm Madaus
RTI Biologics
Sanofi
SBM
Seikagaku
SIGNUS Medizintechnik
Smith & Nephew
Stryker
Synthes
Tecnoss Dental
Tedec-Meiji Farma
Teknimed
TRB Chemedica
Wright Medical Technology
Zimmer
Table of Contents
Table of Contents
TABLE OF CONTENTS
LIST OF FIGURES AND TABLES
EXECUTIVE SUMMARY
1. COUNTRY OVERVIEWS
1.1. France
1.1.1. Demographics and Economy
1.1.2. Health Care System
1.1.3. Regulatory Environment
1.2. Germany
1.2.1. Demographics and Economy
1.2.2. Health Care System
1.2.3. Regulatory Environment
1.3. Italy
1.3.1. Demographics and Economy
1.3.2. Health Care System
1.3.3. Regulatory Environment
1.4. Spain
1.4.1. Demographics and Economy
1.4.2. Health Care System
1.4.3. Regulatory Environment
1.5. UK
1.5.1. Demographics and Economy
1.5.2. Health Care System
1.5.3. Regulatory Environment
2. CLINICAL LANDSCAPE
2.1. Background
2.1.1. Arthritis
2.2. Procedure Descriptions
2.2.1. Bone Graft Procedures
2.2.1.1. Trauma Surgeries
2.2.1.2. Large-Joint Revision and Reconstruction Procedures
2.2.1.3. Thoracolumbar and Cervical Spinal Fusions
12.2. UK Hyaluronic Acid Viscosupplementation Market Snapshot
12.3. Market Shares
APPENDIX: METHODOLOGY
APPENDIX: ACRONYMS AND INITIALISMS
APPENDIX: BIBLIOGRAPHY
LIST OF FIGURES AND TABLES
TABLE OF CONTENTS
LIST OF FIGURES AND TABLES
EXECUTIVE SUMMARY
Figure 1: Orthopedic Biomaterial Market, by Country, Europe (USD), 2011 -
2017
Table 1: Orthopedic Biomaterial Market Landscape, Europe (USD), 2012 and
2017
Table 2: Orthopedic Biomaterial Market Leaders, by Product Type and
Revenue, Europe, 2012
Table 3: Companies Mentioned
Table 4: Factors Impacting the Orthopedic Biomaterial Market, by Product
Type, Europe, 2012 - 2017
Table 5: Recent Novel Devices in the Orthopedic Biomaterial Market, by
Brand, Europe, 2012
Table 6: Expected Key Events in the Orthopedic Biomaterial Market, Europe,
2012 - 2017
Table 7: Key Report Updates
Table 8: Geographies Covered, Europe
Table 9: Average Currency Exchange Rates
Table 10: Orthopedic Biomaterial Procedures Covered, Europe
Table 11: Orthopedic Biomaterial Products Covered, Europe
1. COUNTRY OVERVIEWS
Table 12: Key Health and Economic Indicators, France
Table 13: Key Health and Economic Indicators, Germany
Table 14: Key Health and Economic Indicators, Italy
Table 15: Key Health and Economic Indicators, Spain
Table 16: Key Health and Economic Indicators, UK
2. CLINICAL LANDSCAPE
Table 17: Spinal Nonfusions, by Procedure Type
3. PRODUCTS
Table 18: Characteristics of Bone Grafts, by Material
Table 19: Select First-Generation Synthetic BGS Materials, by Material
Table 20: Advantages and Disadvantages of Bone Grafts, by Material
Table 21: Advantages and Disadvantages of HA Viscosupplementation
Products, by Number of Injections
Table 22: Advantages and Disadvantages of IBDs, by Approach
4. CLINICAL TRIALS
Table 23: Summary of Promoting Fusion in Minimally Invasive Lumbar
Interbody Stabilization with Low-Dose BMP-2 - But What is the Cost?
Table 24: Summary of Spine Fusion Instrumented With BMP-2 vs
Uninstrumented With Infuse BMP-2 Alone
Table 25: Summary of INFUSE Bone Graft/PEEK Interbody Spacer/Anterior
Cervical Plate Pivotal Clinical Trial (ACDF)
Table 26: Summary of Efficacy and Safety of Accell Evo3 DBM in
Instrumented Posterolateral Lumbar Spine Fusion
Table 27: Summary of an Assessment of P-15 Bone Putty in Anterior Cervical
Fusion With Instrumentation
Table 28: Summary of APPRAISET1
Table 29: Summary of Comparing Synthetic Bone Alone versus Synthetic Bone
With Bone Marrow in Bone Lesions
Table 30: Summary of INFUSE Bone Graft in Transforaminal Lumbar Interbody
Fusion for Degenerative Disease of Lumbosacral Spine (TLIF)
Table 31: Summary of SUPARTZ versus Placebo in Osteoarthritis of the
Shoulder Study
Table 32: Summary of Three Injections of EUFLEXXA (Sodium Hyaluronate) for
Treatment of Chronic Shoulder Pain Associated With Osteoarthritis
Table 33: Summary of ORTHOVISC Shoulder RCT (OV Shoulder)
Table 34: Summary of A Double-Blind RCT of a Single Dose of Hyaluronan in
the Treatment of Osteoarthritis of the Ankle
Table 35: Summary of Efficacy of 3 Weekly Injections of Hyaluronate in
Patients With Ankle Osteoarthritis
Table 36: Summary of Intra-Articular Injection of HA in Symptomatic
Osteoarthritis of the Hip
Table 37: Summary of Efficacy of Three Weekly Injections of a Bacterial -
Sourced Hyaluronate on Pain and Function in Patients With Knee Osteoarthritis
Table 38: Summary of Efficacy of Intra-Articular HA in the Knee
Osteoarthritis
Table 39: Summary of Different Volumes of DUROLANE in Knee Osteoarthritis
Table 40: Summary of Comparative Analysis of Intra-articular Injection of
Steroid and/or Sodium Hyaluronate in Adhesive Capsulitis
Table 41: Summary of Efficacy and Safety of 3 Different Dosage Regimens of
HA in Patients with Knee Osteoarthritis
Table 42: Summary of Hymovis Versus Placebo in Knee Osteoarthritis
Table 43: Summary of EVOKE
Table 44: Summary of Growth Factor and Catabolic Cytokine Concentrations
Are Influenced by the Cellular Composition of Platelet-Rich Plasma
Table 45: Summary of Patellar Tendon Healing With Platelet-Rich Plasma: A
Prospective Randomized Controlled Trial
Table 46: Summary of Comparative Assessment of Intra-articular Knee
Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment
of Knee Osteoarthritis
Table 47: Summary of Platelet Rich Plasma (PRP) in Total Knee Replacement
Table 48: Summary of Treatment of Acute and Chronic Ligament and Tendon
Injuries With Platelet Rich Plasma
Table 49: Summary of Use of Platelet Rich Plasma Therapy for Acute Ankle
Sprains in the Emergency Department (PRP)
Table 50: Summary of Platelet Rich Plasma vs. Corticosteroid Injection in
the Treatment of Partial Rotator Cuff Tears
Table 51: Summary of Prospective, Multi-Center Clinical Outcomes Study
Evaluating the chronOS Strip Combined With Bone Marrow Aspirate
5. ORTHOPEDIC BIOMATERIAL MARKET
Figure 2: Orthopedic Biomaterial Market, by Product Type, Europe (USD),
2011 - 2017
Table 52: Factors Impacting the Orthopedic Biomaterial Market, by Product
Type, Europe, 2012 - 2017
Table 53: Orthopedic Biomaterial Market, by Country, Europe (USD, EUR, and
GBP), 2011 - 2017
Table 54: Orthopedic Biomaterial Market, by Product Type, Europe (USD and
EUR), 2011 - 2017
Figure 3: Leading Competitors in the Orthopedic Biomaterial Market, as a %
of Total, Europe, 2012
Table 55: Leading Competitors in the Orthopedic Biomaterial Market, by
Country, as a % of Total, Europe, 2012
Table 56: Leading Competitors in the Orthopedic Biomaterial Market, by
Product Type, as a % of Total, Europe, 2012
Table 57: Recent Events in the Orthopedic Biomaterial Market, Europe
Table 58: Emerging Products in Development for the Orthopedic Biomaterial
Market, Europe, 2012 - 2017
6. BONE GRAFT SUBSTITUTE MARKET
Figure 4: BGS Market, by Material, Europe (USD), 2011 - 2017
Table 59: Bone Graft Procedures, by Country, Europe, 2011 - 2017
Table 60: BGS Procedures, by Country, Europe, 2011 - 2017
Table 61: BGS Market, by Country, Europe (USD, EUR, and GBP), 2011 - 2017
Table 62: Bone Graft Procedures, by Material, Europe, 2011 - 2017
Table 63: BGS Market, by Material, Europe (USD and EUR), 2011 - 2017
Table 64: Average Volume of Bone Graft per Procedure, by Procedure Type,
Europe , 2012
Table 65: Bone Graft Procedures, by Procedure Type, Europe, 2011 - 2017
Table 137: BGS ASPs, by Material, UK (USD, EUR, and GBP), 2011 - 2017
Table 138: BGS Market, by Material, UK (USD, EUR, and GBP), 2011 - 2017
Table 139: BGS ASPs, by Procedure Type, UK (USD, EUR, and GBP), 2011 - 2017
Table 140: BGS Market, by Procedure Type, UK (USD, EUR, and GBP), 2011 -
2017
Figure 21: HA Viscosupplementation Market, by Number of Injections, UK
(USD), 2011 - 2017
Table 141: HA Viscosupplementation Treatments and Injections, by Number of
Injections, UK, 2011 - 2017
Table 142: HA Viscosupplementation Treatments, by Anatomy, UK, 2011 - 2017
Table 143: HA Viscosupplementation Market, by Number of Injections, UK
(USD), 2011 - 2017
Table 144: HA Viscosupplementation Market, by Number of Injections, UK
(EUR), 2011 - 2017
Table 145: HA Viscosupplementation Market, by Number of Injections, UK
(GBP), 2011 - 2017
Table 146: HA Viscosupplementation Market Growth, by Number of Injections,
UK, 2012 - 2017
Table 147: HA Viscosupplementation Market, by Number of Injections, as a %
of Total, UK, 2011 - 2017
Figure 22: Leading Competitors in the Orthopedic Biomaterial Market, as a
% of Total, UK, 2012
Table 148: Leading Competitors in the Orthopedic Biomaterial Market, by
Product Type, as a % of Total, UK, 2012
APPENDIX: METHODOLOGY
APPENDIX: ACRONYMS AND INITIALISMS
Table 149: Acronyms and Initialisms
APPENDIX: BIBLIOGRAPHY
European Markets for Orthopedic Biomaterials 2013 published by Millennium Research Group in November 13, 2012. This report price starts from US $ 7195.
The contents of this page may be different from the latest version. Please contact us for details.
